ロード中...
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis. Despite treatment with eculizumab, a C5 inhibitor, 72% of individuals remain anemic. Pegcetacoplan (APL‐2), a PEGylated C3 inhibitor,...
保存先:
| 出版年: | Am J Hematol |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7693064/ https://ncbi.nlm.nih.gov/pubmed/33464651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25960 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|